Data as of Dec 06
| +1.73 / +1.94%|
The 13 analysts offering 12-month price forecasts for United Therapeutics Corp have a median target of 76.00, with a high estimate of 101.00 and a low estimate of 56.00. The median estimate represents a -16.46% decrease from the last price of 90.97.
The current consensus among 15 polled investment analysts is to Hold stock in United Therapeutics Corp. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.